Zimmer Biomet sank -1.3% this morning, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Zimmer Biomet has logged a 4.0% 52 week change, compared to 16.0% for the S&P 500
-
ZBH has an average analyst rating of hold and is -26.05% away from its mean target price of $150.14 per share
-
Its trailing earnings per share (EPS) is $2.4, which brings its trailing Price to Earnings (P/E) ratio to 46.3. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $8.04 and its forward P/E ratio is 13.8
-
The company has a Price to Book (P/B) ratio of 1.87 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 1.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
ZBH has reported YOY quarterly earnings growth of 37.0% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $1.54 Billion and the average free cash flow growth rate is 0.0%
-
Zimmer Biomet's revenues have an average growth rate of 0.0% with operating expenses growing at -10.5%. The company's current operating margins stand at 17.7%